|
|
|
AZN Description — AstraZeneca Plc
AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in pharmaceutical business focusing on the research, development, manufacturing and commercialization of prescription medicines. Co. is focused on its therapy areas: Oncology, which provides Tagrisso (osimertinib) for lung cancer; BioPharmaceuticals, which provides Farxiga/ Forxiga (dapagliflozin) for Type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease; and Rare Disease, which provides Soliris (eculizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder.
Company Name: |
AstraZeneca Plc |
Website: |
www.astrazeneca.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding AZN: |
19 |
Total Market Value Held by ETFs: |
$1,035,935,399 |
Total Market Capitalization: |
$33,009,000,000 |
% of Market Cap. Held by ETFs: |
3.14% |
|
ETF |
AZN Weight |
AZN Amount |
QQQ |
0.29% |
$725,603,107 |
SPDW |
0.42% |
$82,759,659 |
QQQM |
0.29% |
$64,411,432 |
FVD |
0.60% |
$61,227,623 |
PPH |
5.60% |
$30,288,879 |
TQQQ |
0.12% |
$25,285,327 |
QQEW |
0.97% |
$20,627,019 |
QEFA |
0.85% |
$8,205,854 |
CWI |
0.35% |
$5,509,891 |
BIB |
2.71% |
$2,665,118 |
List of all 19 ETFs holding AZN
» |
|
|
|
|
Buy (3.41 out of 4)
53rd percentile
|
|
|